This article is more than 5 years old. Information may no longer be current.
Molecular control set for C. difficile released
SeraCare Life Sciences has launched a molecular control product that targets hospital-acquired Clostridium difficile, according to a press release.
The Accurun 501 C. difficile Control, is designed for use with in vitro diagnostic tests that detect C. difficile DNA in human stool, the release said. It is SeraCare’s first molecular control product that targets hospital-acquired infections.
Four different strains of cultured Clostridium bacteria are used to manufacture the product, which is delivered ready-to-use in assays that detect C. difficile DNA with any transport system, the release said. The bacteria strains are inactivated, stored in a human synthetic stool matrix and delivered in a set of vials.
“Hospital-acquired infection assays present unique sample challenges which require dependable, whole-cell controls,” Christopher Long, SeraCare product manager, said in the release. “Our new Accurun 501 product is a full-process control that is intended to not only estimate laboratory testing performance but also immediately detect analytical errors and monitor the entire testing process. As a result, our customers have greater confidence in fulfilling their QC requirements.”
The product is available in the US and internationally.